RU2018101722A - Днк-вакцина, нацеленная на vegfr-2, для комбинированной терапии - Google Patents
Днк-вакцина, нацеленная на vegfr-2, для комбинированной терапии Download PDFInfo
- Publication number
- RU2018101722A RU2018101722A RU2018101722A RU2018101722A RU2018101722A RU 2018101722 A RU2018101722 A RU 2018101722A RU 2018101722 A RU2018101722 A RU 2018101722A RU 2018101722 A RU2018101722 A RU 2018101722A RU 2018101722 A RU2018101722 A RU 2018101722A
- Authority
- RU
- Russia
- Prior art keywords
- seq
- protein
- additional
- cancer
- salmonella strain
- Prior art date
Links
- BJHCYTJNPVGSBZ-YXSASFKJSA-N 1-[4-[6-amino-5-[(Z)-methoxyiminomethyl]pyrimidin-4-yl]oxy-2-chlorophenyl]-3-ethylurea Chemical compound CCNC(=O)Nc1ccc(Oc2ncnc(N)c2\C=N/OC)cc1Cl BJHCYTJNPVGSBZ-YXSASFKJSA-N 0.000 title claims 2
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 title claims 2
- 102000016549 Vascular Endothelial Growth Factor Receptor-2 Human genes 0.000 title claims 2
- 238000002648 combination therapy Methods 0.000 title 1
- 229960005486 vaccine Drugs 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 claims 19
- 241000607142 Salmonella Species 0.000 claims 18
- 239000000427 antigen Substances 0.000 claims 16
- 102000036639 antigens Human genes 0.000 claims 16
- 108091007433 antigens Proteins 0.000 claims 16
- 230000002238 attenuated effect Effects 0.000 claims 15
- 125000003275 alpha amino acid group Chemical group 0.000 claims 10
- 108090000623 proteins and genes Proteins 0.000 claims 10
- 102000004169 proteins and genes Human genes 0.000 claims 9
- 108020004414 DNA Proteins 0.000 claims 8
- 102000053602 DNA Human genes 0.000 claims 8
- 108091008605 VEGF receptors Proteins 0.000 claims 4
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 claims 4
- 238000011282 treatment Methods 0.000 claims 4
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 claims 3
- 210000001744 T-lymphocyte Anatomy 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 238000002512 chemotherapy Methods 0.000 claims 3
- 238000011275 oncology therapy Methods 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 238000001959 radiotherapy Methods 0.000 claims 3
- 108010041986 DNA Vaccines Proteins 0.000 claims 2
- 229940021995 DNA vaccine Drugs 0.000 claims 2
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 102000008096 B7-H1 Antigen Human genes 0.000 claims 1
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims 1
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims 1
- 101000576802 Homo sapiens Mesothelin Proteins 0.000 claims 1
- 101000621309 Homo sapiens Wilms tumor protein Proteins 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 102000018697 Membrane Proteins Human genes 0.000 claims 1
- 108010052285 Membrane Proteins Proteins 0.000 claims 1
- 102000003735 Mesothelin Human genes 0.000 claims 1
- 108090000015 Mesothelin Proteins 0.000 claims 1
- 206010027406 Mesothelioma Diseases 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims 1
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- 241001138501 Salmonella enterica Species 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 101710127857 Wilms tumor protein Proteins 0.000 claims 1
- 102100022748 Wilms tumor protein Human genes 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 claims 1
- 238000002619 cancer immunotherapy Methods 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 230000001332 colony forming effect Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 108010072257 fibroblast activation protein alpha Proteins 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 229930027917 kanamycin Natural products 0.000 claims 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 claims 1
- 229960000318 kanamycin Drugs 0.000 claims 1
- 229930182823 kanamycin A Natural products 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 208000015347 renal cell adenocarcinoma Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001109—Vascular endothelial growth factor receptors [VEGFR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001152—Transcription factors, e.g. SOX or c-MYC
- A61K39/001153—Wilms tumor 1 [WT1]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001166—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
- A61K39/001168—Mesothelin [MSLN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00118—Cancer antigens from embryonic or fetal origin
- A61K39/001182—Carcinoembryonic antigen [CEA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0275—Salmonella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Vascular Medicine (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Reproductive Health (AREA)
- Biomedical Technology (AREA)
- Transplantation (AREA)
- Molecular Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15001803 | 2015-06-18 | ||
| EP15001803.4 | 2015-06-18 | ||
| PCT/EP2016/001004 WO2016202459A1 (en) | 2015-06-18 | 2016-06-16 | Vegfr-2 targeting dna vaccine for combination therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2018101722A true RU2018101722A (ru) | 2019-07-18 |
| RU2018101722A3 RU2018101722A3 (https=) | 2019-12-10 |
Family
ID=53476620
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018101722A RU2018101722A (ru) | 2015-06-18 | 2016-06-16 | Днк-вакцина, нацеленная на vegfr-2, для комбинированной терапии |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US10905752B2 (https=) |
| EP (2) | EP3310379B1 (https=) |
| JP (1) | JP6947649B2 (https=) |
| KR (2) | KR20250024816A (https=) |
| CN (1) | CN107995868B (https=) |
| AU (1) | AU2016278588B2 (https=) |
| BR (1) | BR112017027378A2 (https=) |
| CA (1) | CA2989247C (https=) |
| DK (1) | DK3310379T3 (https=) |
| ES (2) | ES2760699T3 (https=) |
| HU (1) | HUE046631T2 (https=) |
| IL (1) | IL256076A (https=) |
| LT (1) | LT3310379T (https=) |
| MX (1) | MX2017016183A (https=) |
| PL (2) | PL3626262T3 (https=) |
| RU (1) | RU2018101722A (https=) |
| SI (1) | SI3310379T1 (https=) |
| WO (1) | WO2016202459A1 (https=) |
| ZA (1) | ZA201708439B (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3041375A1 (en) * | 2016-11-04 | 2018-05-11 | Vaximm Ag | Wt1 targeting dna vaccine for combination therapy |
| WO2018149982A1 (en) * | 2017-02-17 | 2018-08-23 | Vaximm Ag | Novel vegfr-2 targeting immunotherapy approach |
| JP7247097B2 (ja) * | 2017-03-17 | 2023-03-28 | バクシム アクチェンゲゼルシャフト | がん免疫療法のための新規ｐｄ－ｌ１標的ｄｎａワクチン |
| JP7598315B2 (ja) * | 2018-09-05 | 2024-12-11 | エンエーセー オンコイミュニティ アクスイェ セルスカプ | 併用療法用ｄｎａワクチンを標的とするネオアンチゲン |
| US20230121528A1 (en) * | 2020-01-13 | 2023-04-20 | Vaximm Ag | Salmonella-based dna vaccines in combination with an antibiotic |
| EP3922255A1 (en) * | 2020-06-10 | 2021-12-15 | Prokarium Limited | Cancer therapy |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7094410B2 (en) | 2002-03-02 | 2006-08-22 | The Scripps Research Institute | DNA vaccine against proliferating endothelial cells and methods of use thereof |
| NO337687B1 (no) | 2011-07-08 | 2016-06-06 | Norsk Elektro Optikk As | Hyperspektralt kamera og metode for å ta opp hyperspektrale data |
| CA2853656C (en) | 2011-12-22 | 2020-12-29 | Vaximm Ag | Method of producing high yield attenuated salmonella strains |
| JP6325534B2 (ja) * | 2012-07-05 | 2018-05-16 | バクシム アクチェンゲゼルシャフト | 膵臓癌患者用ｄｎａワクチン |
| PL2897620T3 (pl) * | 2012-09-21 | 2020-11-02 | Intensity Therapeutics, Inc | Sposób leczenia nowotworu złośliwego |
| US9974845B2 (en) * | 2013-02-22 | 2018-05-22 | Curevac Ag | Combination of vaccination and inhibition of the PD-1 pathway |
| MX364922B (es) | 2013-04-25 | 2019-05-14 | Vaximm Ag | Vacuna de adn que dirige wt-1 novedosa para inmunoterapia contra cáncer. |
| SI3082850T1 (sl) * | 2013-12-18 | 2020-01-31 | Vaximm Gmbh | DNA cepivo, ki cilja MSLN za imunoterapijo raka |
| WO2018149982A1 (en) * | 2017-02-17 | 2018-08-23 | Vaximm Ag | Novel vegfr-2 targeting immunotherapy approach |
| JP7247097B2 (ja) * | 2017-03-17 | 2023-03-28 | バクシム アクチェンゲゼルシャフト | がん免疫療法のための新規ｐｄ－ｌ１標的ｄｎａワクチン |
-
2016
- 2016-06-16 RU RU2018101722A patent/RU2018101722A/ru not_active Application Discontinuation
- 2016-06-16 HU HUE16736381A patent/HUE046631T2/hu unknown
- 2016-06-16 SI SI201630549T patent/SI3310379T1/sl unknown
- 2016-06-16 BR BR112017027378-0A patent/BR112017027378A2/pt not_active Application Discontinuation
- 2016-06-16 PL PL19205420.3T patent/PL3626262T3/pl unknown
- 2016-06-16 AU AU2016278588A patent/AU2016278588B2/en active Active
- 2016-06-16 PL PL16736381T patent/PL3310379T3/pl unknown
- 2016-06-16 US US15/737,659 patent/US10905752B2/en active Active
- 2016-06-16 ES ES16736381T patent/ES2760699T3/es active Active
- 2016-06-16 DK DK16736381.1T patent/DK3310379T3/da active
- 2016-06-16 KR KR1020257001040A patent/KR20250024816A/ko active Pending
- 2016-06-16 CN CN201680035593.2A patent/CN107995868B/zh active Active
- 2016-06-16 CA CA2989247A patent/CA2989247C/en active Active
- 2016-06-16 EP EP16736381.1A patent/EP3310379B1/en active Active
- 2016-06-16 MX MX2017016183A patent/MX2017016183A/es unknown
- 2016-06-16 EP EP19205420.3A patent/EP3626262B1/en active Active
- 2016-06-16 KR KR1020187001398A patent/KR20180037948A/ko not_active Ceased
- 2016-06-16 JP JP2017565248A patent/JP6947649B2/ja active Active
- 2016-06-16 LT LTEP16736381.1T patent/LT3310379T/lt unknown
- 2016-06-16 WO PCT/EP2016/001004 patent/WO2016202459A1/en not_active Ceased
- 2016-06-16 ES ES19205420T patent/ES2994561T3/es active Active
-
2017
- 2017-12-04 IL IL256076A patent/IL256076A/en unknown
- 2017-12-12 ZA ZA2017/08439A patent/ZA201708439B/en unknown
-
2020
- 2020-11-30 US US17/107,203 patent/US20210077605A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| ZA201708439B (en) | 2021-05-26 |
| BR112017027378A2 (pt) | 2018-08-28 |
| EP3626262A1 (en) | 2020-03-25 |
| US20180250345A1 (en) | 2018-09-06 |
| IL256076A (en) | 2018-01-31 |
| MX2017016183A (es) | 2018-06-19 |
| EP3626262C0 (en) | 2024-10-23 |
| SI3310379T1 (sl) | 2020-02-28 |
| JP2018517419A (ja) | 2018-07-05 |
| EP3310379A1 (en) | 2018-04-25 |
| DK3310379T3 (da) | 2019-12-16 |
| ES2760699T3 (es) | 2020-05-14 |
| WO2016202459A1 (en) | 2016-12-22 |
| ES2994561T3 (en) | 2025-01-27 |
| HUE046631T2 (hu) | 2020-03-30 |
| PL3626262T3 (pl) | 2025-02-17 |
| CA2989247A1 (en) | 2016-12-22 |
| CN107995868B (zh) | 2021-07-13 |
| EP3626262B1 (en) | 2024-10-23 |
| RU2018101722A3 (https=) | 2019-12-10 |
| EP3310379B1 (en) | 2019-11-06 |
| CA2989247C (en) | 2023-10-17 |
| LT3310379T (lt) | 2019-12-27 |
| AU2016278588A1 (en) | 2017-12-21 |
| AU2016278588B2 (en) | 2022-03-31 |
| CN107995868A (zh) | 2018-05-04 |
| US20210077605A1 (en) | 2021-03-18 |
| JP6947649B2 (ja) | 2021-10-13 |
| US10905752B2 (en) | 2021-02-02 |
| HK1252435A1 (en) | 2019-05-24 |
| KR20180037948A (ko) | 2018-04-13 |
| PL3310379T3 (pl) | 2020-03-31 |
| KR20250024816A (ko) | 2025-02-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sivanandam et al. | Oncolytic viruses and immune checkpoint inhibition: the best of both worlds | |
| Li et al. | Multifunctional oncolytic nanoparticles deliver self-replicating IL-12 RNA to eliminate established tumors and prime systemic immunity | |
| Skeate et al. | TNFSF14: LIGHTing the way for effective cancer immunotherapy | |
| Fu et al. | Combination therapy with oncolytic virus and T cells or mRNA vaccine amplifies antitumor effects | |
| Weichselbaum | The 46th David A. Karnofsky Memorial Award lecture: oligometastasis—from conception to treatment | |
| RU2018101722A (ru) | Днк-вакцина, нацеленная на vegfr-2, для комбинированной терапии | |
| Kuryk et al. | Antitumor‐specific T‐cell responses induced by oncolytic adenovirus ONCOS‐102 (AdV5/3‐D24‐GM‐CSF) in peritoneal mesothelioma mouse model | |
| Das et al. | A modular self-adjuvanting cancer vaccine combined with an oncolytic vaccine induces potent antitumor immunity | |
| Liu et al. | Thymosin α1 reverses oncolytic adenovirus-induced M2 polarization of macrophages to improve antitumor immunity and therapeutic efficacy | |
| JP6325534B2 (ja) | 膵臓癌患者用ｄｎａワクチン | |
| RU2016129044A (ru) | Новая вакцина днк, нацеленная на мезотелин, для иммунотерапии рака | |
| Farrera-Sal et al. | Evolving status of clinical immunotherapy with oncolytic adenovirus | |
| Yamano et al. | Whole cell vaccination using immunogenic cell death by an oncolytic adenovirus is effective against a colorectal cancer model | |
| Silva-Pilipich et al. | Intratumoral electroporation of a self-amplifying RNA expressing IL-12 induces antitumor effects in mouse models of cancer | |
| JP2018517419A5 (https=) | ||
| Silva et al. | The combination of ISCOMATRIX adjuvant and TLR agonists induces regression of established solid tumors in vivo | |
| JP2011500718A5 (https=) | ||
| JP2020511139A5 (https=) | ||
| RU2019132253A (ru) | Новая днк-вакцина, нацеленная на pd-l1, для иммунотерапии рака | |
| Wang et al. | Elucidating mechanisms of antitumor immunity mediated by live oncolytic vaccinia and heat-inactivated vaccinia | |
| Zhao et al. | Autologous tumor vaccine modified with recombinant new castle disease virus expressing IL-7 promotes antitumor immune response | |
| Zhang et al. | Recombinant oncolytic adenovirus expressing a soluble PVR elicits long-term antitumor immune surveillance | |
| BR112021001117A2 (pt) | células cancerígenas modificadas, composição farmacêutica, linha celular, métodos para fazer células cancerígenas modificadas e para estimular uma resposta imune, vetor de expressão isolado ou combinação de vetores de expressão isolados, e, uma ou mais células cancerígenas modificadas | |
| Shakiba et al. | Oncolytic therapy with recombinant vaccinia viruses targeting the interleukin-15 pathway elicits a synergistic response | |
| Nguyen et al. | A Listeria-based vaccine targeting ISG15 exerts anti-tumor efficacy in renal cell carcinoma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA94 | Acknowledgement of application withdrawn (non-payment of fees) |
Effective date: 20210817 |